Protocols
HOFFMANN-BO41932-TAPISTRY Phase II OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
IIT-GEORGE-I-PREDICT Phase I/II OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
IIT-GORE-REDIRICT Phase II OPEN TO ACCRUAL
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
MERCK-MK1084-001 Phase I OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors
TAKEDA-TAK-280-1501 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients with Unresectable Locally Advanced or Metastatic Cancer
VMONCOLOGY-VMO-01C Phase I OPEN TO ACCRUAL
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma
XENCOR-XMAB808-01 Phase I OPEN TO ACCRUAL
A Phase 1, First-in-human (FIH), Dose-finding and Expansion Study to Evaluate the Safety and Tolerability of XmAb808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors
XILIO-XTX301-01-02-001 Phase I OPEN TO ACCRUAL
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors